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SPIRONOLACTONE-INDUCED AGRANULOCYTOSIS:
A CASE REPORT
Shu-Hwa Hsiao, Yih-Jyh Lin,1 May-Ying Hsu, and Ta-Jen Wu2
Departments of Pharmacy, 1Surgery, and 2Internal Medicine, National Cheng Kung
University Hospital, Tainan, Taiwan.
A 43-year-old woman with liver cirrhosis and hepatocellular carcinoma was admitted for the chief problem
of ascites. Laboratory data revealed a leukocyte count of 3.8 × 109/L on the second day of admission.
Spironolactone was prescribed for diuresis beginning on the third day. Routine blood tests on the tenth
day disclosed marked leukopenia (1.8 × 109/L). Four days later, the leukocyte count was still 1.8 ×
109/L and a differential count revealed agranulocytosis (neutrophils, 0.25 × 109/L). Eight days after
withdrawal of spironolactone, the leukocyte count returned to normal (leukocytes, 4.9 × 109/L; neutrophils,
1.76 × 109/L). On review of the patient’s clinical condition, concurrent medication, and previous reports,
we highly suspected that this episode of agranulocytosis was caused by spironolactone. Unlike four
previously reported cases, this one did not involve furosemide, which is reported to be associated with
leukopenia and agranulocytosis.
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Drugs are the most common cause of agranulocytosis [1].
Furosemide has been reported to be highly associated with
drug-induced agranulocytosis in a population-based
case-control study [2]. However, only four cases of
spironolactone-induced agranulocytosis have been
previously reported [3–6], all of which were concurrently
treated with furosemide. Here, we report a case of
spironolactone-induced agranulocytosis. To the best of our
knowledge, this is the first case of spironolactone-induced
agranulocytosis without concurrent furosemide therapy.
CASE PRESENTATION
A 43-year-old woman refused chemotherapy after being
diagnosed with hepatocellular carcinoma. She underwent
transarterial embolization 3 months before being admitted
to the National Cheng Kung University Hospital, Taiwan,
on November 19, 2002, for ascites. Jaundice had been noted
for 2 months before admission. Lower abdominal pain with
distension, poor appetite, and oliguria had developed in the
2 weeks prior to presentation. No nausea, vomiting, or
weight loss was observed. Due to the deterioration in her
general condition, she was admitted for further management.
Her vital signs were stable: blood pressure, 98/64 mmHg;
heart rate, 86 beats/minute; and temperature, 37°C.
Laboratory tests on November 20 revealed the following:
leukocytes, 3.8 × 109/L; platelets, 8.9 × 109/L; hemoglobin,
11.7 g/dL; blood urea nitrogen, 8.0 mg/dL; and creatinine,
0.5 mg/dL. Liver function tests showed total bilirubin,
3.9 mg/dL; aspartate aminotransferase, 135 U/L; alanine
aminotransferase, 71 U/L; and albumin, 3.4 g/dL.
The only medication being taken on admission was
silymarin. Tramadol, which was prescribed intermittently
for pain during the past 4 months, was also added on
November 20. Spironolactone 12.5 mg tid was given to
control the ascites from November 21; the dose was increased
to 25 mg tid 2 days later. On November 24, her leukocyte
count was 2.6 × 109/L, platelets were 7.2 × 109/L, and the
white blood cell differential count (WBC-DC) showed
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segments, 77.9%; eosinophils, 1%; basophils, 0.1%;
monocytes, 1.1%; and lymphocytes, 19.9%. On November
28, her leukocyte count was 1.8 × 109/L, platelets were
23.3 × 109/L, and segments were 49.0%.
The exact cause of leukopenia was not identified
immediately. However, because an episode of bleeding
esophageal varices developed, the doctor withdrew
the spironolactone and  tramadol on December 1. The next
day, her leukocyte count was 1.8 × 109/L; platelets, 19.0 ×
109/L; segments, 13.9%; monocytes, 23.0%; and lymphocytes,
58.1%. On December 5, her leukocyte count was 1.9 × 109/L
and platelet count was 19.7 × 109/L, and WBC-DC showed
promyelocytes, 1%; myelocytes, 2%; metamyelocytes, 1%;
bands, 3%; segments, 1%; basophils, 6%; monocytes, 32%;
and lymphocytes, 51% (manual count). On December 9, the
leukocyte count returned to 4.9 × 109/L and the platelet count
to 18.3 × 109/L, and the WBC-DC showed myelocytes, 4%;
metamyelocytes, 2%; bands, 22%; segments, 36%; basophils,
2%; monocytes, 14%; and lymphocytes, 19% (manual count).
The time course for spironolactone administration, leukocyte
counts, and granulocyte counts are shown in the Figure.
The concurrent medication during this period included
a supply of intravenous branched chain amino acids,
tramadol, somatostatin, and terlipressin.
The patient did not receive filgrastim during her
hospitalization. On review of the disease, the patient’s
medication, and previous reports, we highly suspected that
spironolactone was the cause of this episode of
agranulocytosis.
DISCUSSION
The diagnosis of agranulocytosis in this case was certain from
the decrease in granulocytes (absolute neutrophil count, ANC,
decreased to < 500 cells/mm3) after admission to the
normalization of the granulocyte counts with a left shift later
in the serial tests of the complete blood count and WBC-DC.
Acute neutropenia only occurs in a few clinical diseases [1],
and drugs are considered to be the most common cause [1].
No remarkable clinical event in this patient could have
contributed to the neutropenia. She was not given any
chemotherapy for the carcinoma. In addition, she and her
family denied taking any other preparations, except the
prescribed medications in our hospital. Therefore, we highly
suspected that her medication after admission was the
cause of this neutropenia. In view of the clinical course after
the withdrawal of medication, the disappearance of the
neutropenia, and a review of the literature [3–6], we
considered spironolactone to be the cause of this
neutropenia.
In this case, amino acids were given from November 20
to 28 for nutritional support. Somatostatin and terlipressin
were started on November 29 when leukopenia was
observed. Somatostatin was not withdrawn until December
9. Amino acids, somatostatin, and terlipressin are all unlikely
causes of this episode of agranulocytosis. Tramadol was
given from November 20 to December 1. Withdrawal of
spironolactone and tramadol on December 1 was followed
by a normalization of the patient’s white cell count on
December 9. Tramadol had often been used to control the
patient’s abdominal pain without any adverse reaction and
has not been reported to be associated with agranulocytosis.
Of the drugs withdrawn, only spironolactone was newly
instituted and is reported to cause agranulocytosis in the
medical literature.
In this case, agranulocytosis was noted during routine
follow-up of the blood cell count and no specific symptoms
were apparent. Once an adverse reaction is suspected,
discontinuance of the suspected drug followed by
disappearance of the adverse reaction is presumptive
evidence of a drug-induced illness. Confirmatory evidence
may be sought by re-introducing the drug to see if the
reaction reappears. As the adverse effect of agranulocytosis
is life-threatening, re-challenge is not preferred for ethical
reasons. According to Naranjo et al’s adverse drug reaction
algorithm [7], the total agranulocytosis score in this patient
was 7, which is categorized as “probable”.
The mechanisms by which neutropenia develops
after drug administration include decreased production of
Figure. Time course of spironolactone administration, white blood cell
count (◆), and absolute neutrophil count (▲).
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stem cells and immune-mediated peripheral destruction.
Drug toxicity due to the first mechanism is usually dose-
related and dependent on continued administration.
Damage to stem cells or a granulocytic precursor in the
bone marrow prevents differentiation of granulocytes,
without affecting the peripheral pool of neutrophils.
Immune-mediated neutropenia, on the other hand, usually
develops within 7 days of exposure [1]. The bone marrow
tries to compensate for the peripheral destruction of
neutrophils and typically has a normal or hypercellular
appearance.
In the report by Stricker and Oei [4], a bone marrow
biopsy revealed many myelocytes and an absence of mature
granulocytes, supporting a direct toxic effect of the drug on
the bone marrow. However, the patient reported by Jivraj et
al had normal cellularity in the bone marrow [3], suggesting
Table. Comparison of reported cases in the medical literature
Parameters Stricker & Oei Jivraj et al Ferguson et al Whitling et al Hsiao et al
Age (yr) 70 57 65 58 43
Gender F M F F F
Spironolactone dose 100 mg qd 25 mg q6h Not reported 200 mg qd, 25 mg tid
100 mg qn
Furosemide dose 80 mg qd 80 mg bid Not reported 20 mg bid Not combined
Onset 5 wk 4 d 8 d 30 d 7 d
Leukocytes (× 103/mm3) 2.6 2.3 1.64 1.0 1.8
Neutrophils (× 103/mm3) 0 0.14 0.1 0.01 0.25
Recovery 7 d 14 d 5 d 5 d 10 d
Bone marrow biopsy Myelocytes, Normal cellularity Not done Myeloid hypoplasia Not done
absence of mature
granulocytes
Concurrent medications Digoxin Domperidone, Amoxicillin, Glipizide, lactulose, Tramadol,
prochlorperazine, digoxin, multivitamins amino acids,
digoxin, warfarin captopril, somatostatin,
verapamil terlipressin
Diagnosis CHF, renal failure CHF, severe CHF, atrial Cryptogenic Hepatic cirrhosis,
rheumatic heart fibrillation, hepatic cirrhosis hepatocellular
disease, ventricular pleural effusion carcinoma
arrhythmias
F = female; M = male; CHF = congestive heart failure.
peripheral destruction of circulating leukocytes. The clinical
manifestation in our case seems to favor peripheral
destruction of neutrophils. Nonetheless, the mechanism for
spironolactone-induced agranulocytosis should be further
clarified.
Our case shows a similar clinical presentation to that
reported by Jivraj et al (Table). However, our case is the only
one of the five reported that did not involve furosemide,
which is also reported to be associated with leukopenia and
agranulocytosis [2].
In summary, we have reported a case of agranulocytosis
secondary to spironolactone administration without
furosemide therapy in a patient with liver cirrhosis
complicated by hepatocellular carcinoma. We propose that
leukocyte counts be monitored for the first month of
spironolactone therapy.
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